Disruptive innovation in psychiatry.
computational psychiatry
disruptive innovation
microbiome
nanotechnology
psychedelics
quantum computing
Journal
Annals of the New York Academy of Sciences
ISSN: 1749-6632
Titre abrégé: Ann N Y Acad Sci
Pays: United States
ID NLM: 7506858
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
pubmed:
3
3
2022
medline:
22
6
2022
entrez:
2
3
2022
Statut:
ppublish
Résumé
Disruptive innovation is a cornerstone of various disciplines, particularly in the business world, where paradigm-altering approaches are often lauded. As a construct, disruptive psychiatry can be considered to embody such an approach by the pursuit of innovations within the field which test boundaries and shake up the status quo. Given the importance of addressing the current mental health pandemic, and the deficit of highly effective pharmacological treatments for various conditions, innovative disruptive thinking is required. Significant promise exists via the provision of potentially more effective innovative therapeutic options, including digital interventions, psychedelic medicines, microbiome-altering treatments, brain stimulation technology, and nanotechnology-based delivery systems. These approaches may be further advanced by individualization of the treatments using computational technology (including quantum computing, machine learning, and artificial intelligence) and genomics.
Identifiants
pubmed: 35233789
doi: 10.1111/nyas.14764
pmc: PMC9314580
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5-9Informations de copyright
© 2022 The Authors. Annals of the New York Academy of Sciences published by Wiley Periodicals LLC on behalf of New York Academy of Sciences.
Références
Trends Neurosci. 2013 May;36(5):305-12
pubmed: 23384445
Front Pharmacol. 2021 Apr 21;12:623979
pubmed: 33967757
Nat Commun. 2020 Jul 3;11(1):3338
pubmed: 32620901
Arch Gerontol Geriatr. 2021 Jan - Feb;92:104260
pubmed: 32980574
Nat Commun. 2021 May 11;12(1):2631
pubmed: 33976136
Arch Gen Psychiatry. 2010 Dec;67(12):1211-24
pubmed: 21135322
Nat Methods. 2021 Jul;18(7):701-709
pubmed: 33398186
JAMA. 2021 Dec 21;326(23):2434-2435
pubmed: 34932084
Int J Neuropsychopharmacol. 2019 Jan 1;22(1):37-52
pubmed: 30099552
Nat Commun. 2019 Nov 5;10(1):4785
pubmed: 31690797
Mayo Clin Proc Innov Qual Outcomes. 2018 May 02;2(2):99-102
pubmed: 30225439
Biomark Med. 2016;10(4):431-43
pubmed: 26999493
N Engl J Med. 2021 Apr 15;384(15):1402-1411
pubmed: 33852780
Aust N Z J Psychiatry. 2021 Dec;55(12):1127-1133
pubmed: 33745287
World Psychiatry. 2021 Oct;20(3):318-335
pubmed: 34505369
Hum Brain Mapp. 2021 Sep;42(13):4155-4172
pubmed: 33544411
Eur Neuropsychopharmacol. 2013 Sep;23(9):1067-71
pubmed: 23183130
Nat Med. 2021 Jun;27(6):1025-1033
pubmed: 33972795
Psychopharmacology (Berl). 2021 Feb;238(2):341-354
pubmed: 33427944
Int J Mol Sci. 2020 Feb 01;21(3):
pubmed: 32024055
Int J Ment Health Syst. 2020 Nov 11;14(1):83
pubmed: 33292354
World Psychiatry. 2020 Oct;19(3):360-380
pubmed: 32931092
BMC Med. 2020 Nov 12;18(1):354
pubmed: 33176802